Mammalian target of rapamycin as a therapeutic target in leukemia

Area of Science:

• Molecular Biology
• Oncology
• Cell Signaling

Background:

• The mammalian target of rapamycin (mTOR) is a key signaling pathway linking cell growth and division to nutrient availability.
• mTOR is a downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.
• Constitutive activation of PI3K/Akt kinases is observed in human leukemias, with pathways like FLT3, VEGF, and BCR-ABL mediating activity via mTOR.

Purpose of the Study:

• To investigate the role of mTOR in cell growth and division.
• To explore the therapeutic potential of mTOR inhibitors in hematologic malignancies.

Main Methods:

• The study discusses the downstream signaling of mTOR, including the activation of 40S ribosomal protein S6 kinase (p70s6k) and eukaryotic initiation factor 4E-binding protein-1.
• It examines the effects of mTOR inhibition on cell cycle regulators like cyclin-dependent kinase (CDK) activation, retinoblastoma protein phosphorylation, and cyclin D1 turnover.
• The abstract mentions the use of new rapamycin analogs (CCI-779, RAD001, AP23573) in clinical studies.

Main Results:

• mTOR inhibition leads to the prevention of cyclin-dependent kinase (CDK) activation.
• Inhibition also results in decreased retinoblastoma protein phosphorylation and accelerated turnover of cyclin D1.
• This culminates in a deficiency of active CDK4/cyclin D1 complexes, potentially causing G1 phase arrest.

Conclusions:

• mTOR plays a critical role in cell growth and division by integrating signals from the cellular nutritional environment.
• Inhibition of the mTOR pathway can lead to cell cycle arrest, offering a potential therapeutic strategy for cancers.
• Novel rapamycin analogs are under investigation in clinical trials for treating hematologic malignancies, highlighting the therapeutic relevance of targeting mTOR.